Phase 3 vs Approved — Rare Disease Deal Valuation Comparison

Phase 3 Median Upfront

$971M

Total: $3.4B

Approved Median Upfront

$2.6B

Total: $6.3B

Stage Premium

87%

Approved premium over Phase 3

Phase 3 Royalties

11.2%-20.1%

vs Approved: 16.8%-30%

Model Your Deal

Market Analysis

The Phase 3 to Approved transition in rare disease represents a significant value inflection point. Approved deals carry a median total deal value of $6.3B compared to $3.4B at Phase 3, a 87% premium reflecting clinical de-risking. Upfront payments increase from $971M to $2.6B.

Deal structures shift as assets advance. Phase 3 deals allocate 29% to upfront and 71% to milestones, while Approved deals shift to 41%/59%. Development milestones move from $239M to $186M, and royalty rates evolve from 11.2%-20.1% to 16.8%-30%.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the deal value premium from Phase 3 to Approved in rare disease?

Approved rare disease deals command a 87% premium over Phase 3 in total deal value ($6.3B vs $3.4B). Upfronts increase from $971M to $2.6B, reflecting the de-risking value of clinical progression.

How do deal structures differ between Phase 3 and Approved in rare disease?

Phase 3 deals are more milestone-weighted (71% milestones), reflecting higher clinical risk. Approved deals shift toward higher upfront allocations (41% upfront) as clinical de-risking reduces the need for contingent milestone structures.

When is the optimal time to license a rare disease asset?

The optimal licensing window depends on strategic priorities. Phase 3 assets offer lower entry cost for licensees, while Approved assets provide more certainty. The 87% premium from Phase 3 to Approved reflects the value created by clinical data, making the transition point critical for deal timing.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included